Mirum Pharma Q2 Product Sales Up 38%; Net Loss $(67.2M) on Acquisition

Mirum Pharmaceuticals reported a 38% increase in Q2 2026 product sales, reaching $176.2 million, driven by strong performance from Livmarli and Bile Acid Medicines. However, the company posted a net loss of $(67.2) million, or $(1.06) per share, primarily due to a significant $742.7 million year-to-date acquired in-process research and development expense related to the acquisition of Bluejay Therapeutics in January 2026. As of June 30, 2026, Mirum held $561.3 million in unrestricted cash, cash equivalents, and investments, which it believes is sufficient for at least the next twelve months.